Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 16, 2020 08:30 ET | Source: BioCardia

BioCardia, Inc. Announces $10.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SAN CARLOS, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA) (BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the...
December 15, 2020 01:21 ET | Source: BioCardia

BioCardia, Inc. Announces $8.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules [Revised]

SAN CARLOS, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the...
December 14, 2020 15:21 ET | Source: BioCardia

BioCardia, Inc. Announces $8.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the...
December 14, 2020 08:00 ET | Source: BioCardia

BioCardia Anticipates DSMB Feedback on Interim Data From Pivotal Phase 3 CardiAMP Heart Failure Trial

SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announces that it anticipates data safety monitoring board (DSMB) verbal...
December 01, 2020 07:00 ET | Source: BioCardia

BioCardia Reports Published Study Showing Helix Biotherapeutic Delivery System Used in CardiAMP Phase III Heart Failure Trial Has Fewest Adverse Events Among Competitive Delivery Systems

SAN CARLOS, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] today announced that the Company’s proprietary Helix Biotherapeutic Delivery System (the Helix System)...